Abstract
Histamine is a key mediator of allergic inflammation, primarily through competitive antagonism of binding to H1 receptors. In this issue, Weller and Maurer report that the H1 antagonist desloratadine possesses mast cell-stabilizing properties when challenged in an IgE-dependent or-independent fashion. Thus, desloratadine provides benefits that are independent of H1 receptor binding and based on mast cell stabilization.
| Original language | English |
|---|---|
| Pages (from-to) | 2549-2551 |
| Number of pages | 3 |
| Journal | Journal of Investigative Dermatology |
| Volume | 129 |
| Issue number | 11 |
| DOIs |
|
| State | Published - Nov 2009 |
Bibliographical note
Funding Information:F. Levi-Schaffer is the recipient of grant funds from the Aimwell Charitable Trust (UK), the Israel Science Foundation, and the Israel Ministry of Health. Dr Levi-Schaffer is a member of the David R Bloom Center for Pharmacy and the Dr Adolph and Klara Brettler Center for Research in Molecular Pharmacology and Therapeutics in the School of Pharmacy, the Hebrew University of Jerusalem.